Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.
作者信息
Loscocco Giuseppe G
机构信息
CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
出版信息
Int J Hematol. 2020 Jul;112(1):125-126. doi: 10.1007/s12185-020-02895-w. Epub 2020 May 30.
Abstract
摘要
相似文献
1
Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.继发性噬血细胞性淋巴组织细胞增生症、HScore与2019冠状病毒病
Int J Hematol. 2020 Jul;112(1):125-126. doi: 10.1007/s12185-020-02895-w. Epub 2020 May 30.
2
Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.低剂量依托泊苷疗法对新型冠状病毒肺炎相关噬血细胞性淋巴组织细胞增生症的潜在作用
Int J Hematol. 2020 Jul;112(1):122-124. doi: 10.1007/s12185-020-02888-9. Epub 2020 May 12.
3
Reply to the letter by Gaetano Loscocco, Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.对盖埃塔诺·洛斯科科来信的回复，继发性噬血细胞性淋巴组织细胞增生症、HScore与2019冠状病毒病
Int J Hematol. 2020 Jul;112(1):127. doi: 10.1007/s12185-020-02896-9. Epub 2020 May 28.
4
Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19.托珠单抗用于一名合并 COVID-19 的肾移植受者的噬血细胞综合征
Ann Intern Med. 2020 Sep 15;173(6):501-503. doi: 10.7326/L20-0419. Epub 2020 May 18.
5
Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis.严重 COVID-19 合并噬血细胞性淋巴组织细胞增生症患者对阿那白滞素的良好反应。
Cell Host Microbe. 2020 Jul 8;28(1):117-123.e1. doi: 10.1016/j.chom.2020.05.007. Epub 2020 May 14.
6
Silencing of immune activation with methotrexate in patients with COVID-19.使用甲氨蝶呤使新冠肺炎患者的免疫激活沉默。
J Neurol Sci. 2020 Aug 15;415:116942. doi: 10.1016/j.jns.2020.116942. Epub 2020 May 25.
7
Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients.依托泊苷作为免疫抑制剂的辅助治疗用于危重症COVID-19患者。
J Infect. 2020 Sep;81(3):452-482. doi: 10.1016/j.jinf.2020.06.006. Epub 2020 Jun 21.
8
Haemophagocytic lymphohistiocytosis in COVID-19 cases?新冠病毒感染病例中的噬血细胞性淋巴组织细胞增生症？
Tidsskr Nor Laegeforen. 2020 Mar 23;140(6). doi: 10.4045/tidsskr.20.0240. Print 2020 Apr 21.
9
[Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].[在重症新型冠状病毒肺炎患者中使用JAK 1/2抑制剂的理论依据]
Ugeskr Laeger. 2020 Jun 15;182(25).
10
Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.新冠病毒相关细胞因子风暴的潜在治疗方法——超越皮质类固醇
Front Immunol. 2020 Jun 16;11:1445. doi: 10.3389/fimmu.2020.01445. eCollection 2020.
引用本文的文献
1
COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.COVID-19 与贫血和血液系统恶性肿瘤患者：风险因素、临床指南和新兴治疗方法。
Cell Commun Signal. 2024 Feb 15;22(1):126. doi: 10.1186/s12964-023-01316-9.
2
Common bone marrow signature in COVID-19-associated multisystem inflammatory syndrome in children: A first-wave small case series experience.儿童 COVID-19 相关多系统炎症综合征的常见骨髓特征：第一波小病例系列经验。
Pediatr Blood Cancer. 2022 Nov;69(11):e29919. doi: 10.1002/pbc.29919. Epub 2022 Aug 20.
3
COVID-19 and the differences in physiological background between children and adults and their clinical consequences.COVID-19 与儿童和成人在生理背景上的差异及其临床后果。
Physiol Res. 2021 Dec 16;70(S2):S209-S225. doi: 10.33549/physiolres.934759.
4
Association of HScore Parameters with Severe COVID-19: A Systematic Review and Meta-Analysis.HScore参数与重症新型冠状病毒肺炎的关联：一项系统评价与Meta分析
Iran J Med Sci. 2021 Sep;46(5):322-338. doi: 10.30476/IJMS.2021.88404.1910.
5
Longitudinal monitoring of laboratory markers characterizes hospitalized and ambulatory COVID-19 patients.对住院和门诊 COVID-19 患者的实验室标志物进行纵向监测。
Sci Rep. 2021 Jul 14;11(1):14471. doi: 10.1038/s41598-021-93950-x.
6
Systemic and organ-specific immune-related manifestations of COVID-19.COVID-19 的全身性和器官特异性免疫相关表现。
Nat Rev Rheumatol. 2021 Jun;17(6):315-332. doi: 10.1038/s41584-021-00608-z. Epub 2021 Apr 26.
7
Haemophagocytic syndrome and COVID-19.噬血细胞综合征与 COVID-19。
Clin Rheumatol. 2021 Apr;40(4):1233-1244. doi: 10.1007/s10067-020-05569-4. Epub 2021 Jan 3.
8
COVID-19-associated coagulopathy and disseminated intravascular coagulation.COVID-19 相关凝血功能障碍和弥散性血管内凝血。
Int J Hematol. 2021 Jan;113(1):45-57. doi: 10.1007/s12185-020-03029-y. Epub 2020 Nov 7.
本文引用的文献
1
Is the HScore useful in COVID-19?HScore在新冠病毒疾病（COVID-19）中有用吗？
Lancet. 2020 May 16;395(10236):e83. doi: 10.1016/S0140-6736(20)31057-6. Epub 2020 May 5.
2
Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.低剂量依托泊苷疗法对新型冠状病毒肺炎相关噬血细胞性淋巴组织细胞增生症的潜在作用
Int J Hematol. 2020 Jul;112(1):122-124. doi: 10.1007/s12185-020-02888-9. Epub 2020 May 12.
3
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
4
Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome.HScore 的制定与验证：一种用于诊断反应性噬血细胞综合征的评分系统。
Arthritis Rheumatol. 2014 Sep;66(9):2613-20. doi: 10.1002/art.38690.
Zotero 插件